

ASX Release

Anatara Investor Presentation and Update

Key points:

- **On track to lodge for regulatory approval for Detach™ in Australia**
- **Expanded executive team on board**
- **Targeting livestock focus past just pigs, to cattle & poultry**
- **Looking to attract new institutional interest**
- **Increasing focus on key human applications**
- **Strong balance sheet**

BRISBANE, 11th July 2016: Anatara Lifesciences (ASX:ANR) releases its latest institutional roadshow presentation and market update. This week CEO & Chairman Dr Mel Bridges and Co-Founder and Chief Scientific Officer (CSO) Dr Tracey Mynott will be conducting a roadshow updating existing and potential new institutional investors and analysts.

Dr Bridges said, “As Anatara continues to deliver on its milestones and builds its share price to more than two times its issue price less than two years ago, the company is starting to attract new institutional and high net-worth interest in the company.”

“We are also looking to expand analyst research coverage on ANR. This week’s roadshow is about building our brand awareness as the company increases its focus on gastrointestinal (gut) opportunities for its core therapeutic compounds in the human area as well as expanding applications in replacing antibiotics in the livestock area,” Dr Bridges added.

The new executive team appointments will allow the Anatara team more time to focus on moving the animal health initiatives to completion, as the Company increases its over-the-counter (OTC) opportunities in the human area.

“With a strong balance sheet, we are set to move Anatara significantly forward on all fronts. We have completed our forward 3 year plan projections and remain committed to continuing to execute on our key milestones,” Dr Bridges added.

ENDS



For more information please contact:

Investor inquiries	Media inquiries
<p>Dr Mel Bridges Chairman, Anantara Lifesciences +61 (0) 413 051 600 melbridges@parmacorp.com</p> <p>Dr Tracey Mynott CSO, Anantara Lifesciences +61 (0) 405 050 113 tmynott@anataralifesciences.com</p>	<p>Jane Lowe IR Department +61 (0) 411 117 774 jane.lowe@irdepartment.com.au</p>

About Anantara Lifesciences

Anantara Lifesciences is developing therapeutics for gastrointestinal diseases in production animals and humans. Its lead product Detach™ is a natural plant based product that will help address global concerns around the overuse of antibiotics in production animals that is contributing to the rise of so-called “super bugs” that make infectious diseases harder to treat. The Anantara team has a strong track record in biological science as well as building and growing international biotech companies.



ANATARA
LIFESCIENCES

Natural Alternative to Antibiotics

July 2016



Disclaimer

The information in this presentation does not constitute personal investment advice. The presentation is not intended to be comprehensive or provide all information required by investors to make an informed decision on any investment in Anantara Lifesciences Ltd, ACN 145 239 872 (Company). In preparing this presentation, the Company did not take into account the investment objectives, financial situation and particular needs of any particular investor.

Further advice should be obtained from a professional investment adviser before taking any action on any information dealt with in the presentation. Those acting upon any information without advice do so entirely at their own risk.

Whilst this presentation is based on information from sources which are considered reliable, no representation or warranty, express or implied, is made or given by or on behalf of the Company, any of its directors, or any other person about the accuracy, completeness or fairness of the information or opinions contained in this presentation. No responsibility or liability is accepted by any of them for that information or those opinions or for any errors, omissions, misstatements (negligent or otherwise) or for any communication written or otherwise, contained or referred to in this presentation.

Neither the Company nor any of its directors, officers, employees, advisers, associated persons or subsidiaries are liable for any direct, indirect or consequential loss or damage suffered by any person as a result of relying upon any statement in this presentation or any document supplied with this presentation, or by any future communications in connection with those documents and all of those losses and damages are expressly disclaimed.

Any opinions expressed reflect the Company's position at the date of this presentation and are subject to change.



Key Financial Details

ASX Code	ANR
----------	-----

Share Price	\$1.20
-------------	--------


Market Cap	\$59.1 million
------------	----------------

Ordinary Shares	49,288,246
-----------------	------------

Current Cash	\$13.3 million
--------------	----------------



ANR Share Price Chart



Oral therapeutics for gastrointestinal disease in livestock and humans

Detach™

- Natural, non-antibiotic therapeutic that prevents and treats gastrointestinal diseases including diarrhoea
- Meets the need to reduce antibiotics in animal production
- Unlike antibiotics, Detach™ will not contribute to antimicrobial resistance




Need to combat anti-microbial resistance

- Anti-microbial resistance is a worldwide threat to public health
- Tens of thousands of people die every year because of antibiotic resistant bacteria – so called “Super Bugs”
(USA CDC, WHO)
- Antibiotic resistance is driven by antibiotic overuse — in man and animals
- World authorities are banning growth promoting antibiotics and restricting prophylactic antibiotics in animal production




Lead Indication – Pigs

Diarrhoea affects hundreds of millions of piglets born each year



Market Opportunity is clear

- Growing awareness of urgent need to combat anti-microbial resistance
- Demand for non-antibiotic treatments will rise as authorities act to restrict/ban use of antibiotics in farm animals
- Global animal antibiotic market valued at ~ \$4.63 billion in 2014¹. Production animals 70%. Pigs lead by market share of 25%.
- Consumers want their meat to be safe and retailers are demanding antibiotic free produce
- Pork producers need effective alternatives to antibiotics
- Pork is #1 consumed meat in the world. Global demand for meat is rising
- Detach™ can be developed for chickens, calves and humans




Consumer Pressure

- Food Quality & Food Safety



- McDonald's will stop buying chicken reared on antibiotics used in humans within two years (*March 2015*).
- McDonald's is the largest restaurant chain in the world — this move had a major impact on other retailers and will now affect consumer expectations – and how animals are reared.



Consumer Pressure

ConsumerReports[®] meat on drugs



Anatara – A solution


- Detach™ is an orally administered non-antibiotic anti-infective
- Proven efficacy – evidence-based therapeutic claims
- Proven safety - active ingredient is a natural plant based product
- Broad acting against a range of causes of diarrhoea
- Stable - does not require refrigeration
- Unlike antibiotics, Detach™ will not lead to antimicrobial resistance
- Proven economic benefits for farmers
- Strong Intellectual Property portfolio
- Peer-reviewed publications in high impact academic journals



Detach™ Mode of action

Detach™ does not target the pathogen

Detach™ acts on the underlying cause of diarrhoea



1. Chandler and Mynott. 1998. *Gut* 43:196-202.
2. Mynott, et al., *Gut* 38:28-32.
3. Mynott, et al. 1997. *Gastroenterol.* 113:175-184.
4. Mynott et al. 1999. *J. Immunol.* 163:2568-2575

Detach™

Poised for swift market entry

- Launch planned in Australia for 2017
- Has a clear path to market
 - *Proven efficacy (therapeutic claims)*
 - *Proven safety - active ingredient is GRAS (generally recognised as safe)*
 - *Manufacturing complete at commercial scale and global supply confirmed*
 - *Regulatory route defined*
- Addresses a major demand – Need for non-antibiotic alternatives
- Introduction of Detach™ is supported by Industry, Government, Retailer & Consumer demand



Current 50 kg scale
(≈500,000 doses)



1,000 kg capacity
(≈8,500,000 doses)

Exclusive Option to license Detach™ for worldwide commercialisation with Zoetis

- Aggressive program for evaluation of Detach™ in multiple livestock species
- Zoetis will fund cost of validation trials
- Upfront and subsequent cash payments
- Further strengthens Anatarra Balance Sheet
- IP remains the sole property of Anatarra
- Anatarra retains rights to AUS and NZ
- Validation of Detach™ technology



Zoetis at a glance



- Zoetis (zō-EH-tis) are the **#1 global animal health company**
- **60+ years** of experience in animal health
- **120+ countries** in which Zoetis products are sold
- **~\$5 billion** annual revenue
 - 65% revenue from farm animal products
 - 34% revenue from companion animal products
- **10,000 staff** including 3600+ field force
- **8 animal species** – cattle, swine, poultry, sheep, fish, dogs, cats and horses
- **5 product categories** – anti-infectives, vaccines, medicinal feed additives, parasiticides & other pharmaceutical products



What Next?


Anatara - A Pipeline in a Product

- Other Detach™ presentations:
 - Livestock in-feed
 - Livestock in-water

Potential product extensions for the core components of Detach™

Partnering Opportunities for:

- Companion animals (cats & dogs – eg. atopic dermatitis)
- Over-the-Counter (OTC) for humans (diarrhoea; anti-inflammatory, eg. inflammatory bowel disease, irritable bowel syndrome)
- Human therapeutic (diarrhoea; anti-inflammatory, eg. IBD, IBS; cancer; lupus)





ANATARA
LIFESCIENCES

Human Applications

There are 4 billion episodes of diarrhoea in the world annually.

Diarrhoea is the second cause of death in children under 5 years, and the leading cause of malnutrition.



Human Applications

- No product available that prevents all causes of GI diseases
- Diversity of diarrhoea poses a difficulty for drug developers

Gastro Related Disorders/Diseases

- Inflammatory bowel disease (1.4 million in USA, 2.3 million in EU & Australia)
- Irritable bowel syndrome (10% - 15% of population)

Traveller's Diarrhoea


- >50 million Traveller's at risk per year, rising to >100 million by 2020.
- TD is a threat to military efficiency, and development preventative treatment is a priority for the US Army

Developing Countries


- Second cause of death in under 5's; 1.3 million deaths per year.
- Leading cause of malnutrition; physical and cognitive development issues.
- Significant risk factor following natural disasters.

USA

- ~ 211-375 million episodes of diarrhoea each year.
- 116 million people take anti-diarrhoea medication (31%). 19 million received anti-microbial (5%)



Upcoming Milestones



Anatara Investment Overview

- Experienced Board and management team with proven track record
- Lead product, Detach™ has a clear route to market:
 - Commercially validated and proven efficacy
 - Development strategy de-risked and revenues within 2 years
- Well funded – sufficient to launch Detach™ in AU, EU and USA
- Product pipeline – animal product leads to human product development for partnering / licensing
- Seasoned Operational Team:
 - Regulatory – *Experienced Australia, EU and USA Team*
 - Manufacturing - *TGA and APVMA licensed GMP facility. FDA audited.*
 - Clinical Trials - *Department of Environment and Primary Industries*
 - Commercial + Sales & Marketing





ANATARA
LIFESCIENCES

Thank you

“With the world’s meat production needs set to rise 100% by 2050, it is important we act now to develop non-antibiotic treatment options.”

Dr Mel Bridges, Chairman – Anatara Lifesciences



Questions


Dr Mel Bridges, CEO, Chairman & Co-founder
mbridges@anataralifesciences.com
+61 413 051 600

Dr Tracey Mynott, CSO & Co-founder
tmynott@anataralifesciences.com
+61 405 050 113



Intellectual Property

- PCT application filed (August 2015)
- Second USA patent filed (August 2015)
- Solid patent strategy in place for further patents to be filed in major territories
- Claims cover the Detach™ formulation, as well as use of the active ingredient and composition of matter for the active components within Bromelain-Rx
- Bromelain-Rx is not the same as common bromelain
- Detach™ formulation has superior efficacy to bromelain or bromelain-Rx alone



IP wall of China



Field Trial Summary



Previous Trials

- 20 positive field trials on commercial farms
- Detach™ safe and effective in several thousand piglets

Registration Trials

- Successful trial in Spain (ANR 12-001)
- Successful trial in Northern Victoria (ANR 14-001)
- Successful trial in South East Queensland (ANR 15-001)
- Successful results in different age groups, in different geographical locations and under different clinical scenarios (mild and severe conditions)
- Final trial – farm selected and in advanced planning (Back up sites under evaluation)

DETACH™ FIELD TRIALS



First Australian Registration Trial – ANR 14-001

- 1200 sow farm had a history of problems with pre-weaning scour
- Current approaches such as sow vaccines and antibiotics failed to control the problem
- Trial was blinded, randomised and placebo controlled
 - Group 1 – Detach™, 21 litters (233 piglets)
 - Group 2 – Control, 23 litters (229 piglets)
- Trial designed to meet Australian regulatory requirements (APVMA) and on farms owned by key pork industry opinion leaders



ANR 14-001 Field Trial – Key Results

Detach™ reduced deaths

- Detach reduced deaths by approximately 50%
 - 92% of Detach™ pigs weaned (or 20 more piglets)
 - 85% of control piglets weaned
- Number of piglets weaned per litter is a KPI for the pork industry
- Each weaned piglet has a value of \$150 to \$170
- High mortality rate on this farm, so a severe test for Detach

Detach™ improved weights

- Detach™ improved weight gain by 5.7% (or 224 g per pig)
- Detach™ treated group - 118 kg more meat
extrapolated to slaughter = 10×0.75 (carcass weight) = 885 kg
- Data consistent with earlier field trial on commercial pig farm
 - supports registration



ANR 14-001 Results

- Detach™ significantly reduced piglet mortality by 47.8%
- Detach™ reduced severe morbidity, or life threatening disease

Table 1 – Pre-weaning morbidity and mortality

Treatment	No. Pigs	Morbidity Score 4*	No. deaths	% mortality ¹
Detach™	233	28	19	8.2%
Untreated	229	38	36	15.7%

% reduction 47.8%

*Score 4 - pigs with life threatening disease (p=0.20 ns)

¹p<0.02



ANR 14-001 Results

Detach™ increased the average weight of each piglet at Day 21 by 224 g (5.7%)

Table 2 - Weight gains and ADG from Day 2 to Day 21

Treatment	No. Pens	Litter size (Day 21)	Average Weight Gain (g) (min – max)	Average ADG (g/day) (min – max)
Detach	21	10.19	4,188 (2,512 to 5,279)	199 (120 to 251)
Untreated	23	8.48	3,964 (939 to 5,205)	189 (45 – 248)
		% increase	5.7%	5.6%



Second Australian Re-registration Field Trial – ANR 15-001

- Grower facility had a history of problems with post-weaning disease due to *E. coli*
- Trial was blinded, randomised and placebo controlled
 - Group 1 – Detach™, 20 pens (280 piglets)
 - Group 2 – Control, 20 pens (280 piglets)
- Despite history of disease pre-study, disease incidence dramatically reduced during the study.
- No antibiotic treatments required to treat scour



ANR 15-001 Results

Table 1 – Scour morbidity and mortality

Treatment	No. Pigs	Scour frequency	Scour severity	No. deaths
Detach™	280	89	96	0
Untreated	280	152	173	4

% reduction

41.4%*

44.5%*

*p<0.02

Table 2 - Weight gains and ADG from Day 21 (weaning) to Day 49

Treatment	No. Pens	Pen size	Average Weight Gain (kg) (s.d)	Average ADG (g/day) (min – max)
Detach™	20	14	7.1 (± 0.7)	252.1 (± 25.35)
Untreated	20	14	7.0 (± 0.7)	249.6 (± 26.3)
			1.4%	1%



Competition and Limitations

Description	Example	Limitations
Antibiotics	Trimethoprim/sulfadoxine, Neomycin, Lincospectin (\$0.31 to \$3.50/pig)	Contributes to AMR/residues Not effective against viruses
Antimicrobial	Zinc Oxide (widely used although not approved in Australia) (\$0.34 / pig)	Antimicrobial resistance Environmental issues/residues Reduced palatability Quality control issues Not approved in all countries
Vaccines	Autogenous Multivalent Pathogen specific (up to \$3.00 per pig)	Pathogen specific Prevention only
Non-specific	Organic acids Essential oils Probiotics	Variable efficacy

